Publication
Antibodies towards high-density lipoprotein components in patients with psoriasis
| dc.contributor.author | Paiva-Lopes, MJ | |
| dc.contributor.author | Batuca, J | |
| dc.contributor.author | Gouveia, S | |
| dc.contributor.author | Alves, M | |
| dc.contributor.author | Papoila, AL | |
| dc.contributor.author | Alves, JD | |
| dc.date.accessioned | 2019-10-28T14:53:56Z | |
| dc.date.available | 2019-10-28T14:53:56Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Psoriasis is a chronic inflammatory immune disorder associated with an increased risk of atherosclerosis. This increased risk is not fully understood. High-density lipoproteins (HDL) play an important role in the prevention of atherosclerosis and any factors that may hamper HDL function such as anti-HDL antibodies (aHDL) might be associated with an increased cardiovascular risk. We aimed to determine whether anti-HDL antibodies (aHDL) are present in patients with psoriasis. Sixty-seven patients with psoriasis were compared with a healthy control group. Epidemiologic and clinical data were recorded. IgG and IgM aHDL, IgG anti-apolipoprotein A-I (aApoA-I), anti-apolipoprotein E (aApoE), and anti-paraoxonase 1 (aPON1) antibodies, as well as VCAM-1, IL-6, and TNF-α were assessed by ELISA. Apolipoprotein A-I (ApoA-I) and Apolipoprotein E (ApoE) were measured by immunoturbidimetric immunoassay. Patients with psoriasis had higher titers of IgG aHDL (p < 0.001), IgG aApoA-I (p = 0.001) and aApoE antibodies (p < 0.001). IgG aHDL and aApoE titers were higher in patients with severe psoriasis (p = 0.010 and p = 0.018, respectively). Multiple regression analysis, considering all clinical and biological variables, showed that aApoE, IL-6, and aPON1 are the biological variables that best explain aHDL variability. This is the first report showing the presence of aHDL, aApoA-I, and aApoE antibodies in patients with psoriasis. These antibodies were associated with increased disease severity and may contribute to the pathogenesis of atherosclerosis in psoriasis. They may fulfill the clinical need for biomarkers of cardiovascular risk associated with psoriasis that would help to stratify patients for prevention and therapeutic approaches. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Arch Dermatol Res. 2019 Oct 14. | pt_PT |
| dc.identifier.doi | 10.1007/s00403-019-01986-x | pt_PT |
| dc.identifier.issn | 1432-069X | |
| dc.identifier.uri | http://hdl.handle.net/10400.10/2314 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Springer Verlag | pt_PT |
| dc.subject | Atherosclerosis | pt_PT |
| dc.subject | Psoriasis | pt_PT |
| dc.title | Antibodies towards high-density lipoprotein components in patients with psoriasis | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Berlin | pt_PT |
| oaire.citation.title | Archives of Dermatological Research | pt_PT |
| rcaap.rights | closedAccess | pt_PT |
| rcaap.type | article | pt_PT |